Recent Updates
Recently added Catalysts
DCTH Positive Sentiment

Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment

Wednesday, November 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Delcath Systems, Inc. announced its feature on 'Health Uncensored with Dr. Drew' focusing on liver cancer treatment. The segment, titled 'Precision Oncology: Changing the Game for Metastatic Liver Cancer,' is set to air on November 15, 2026. A podcast will follow the television broadcast.

Market Sentiment Analysis

POSITIVE FACTORS

  • Delcath Systems will be featured on a national television segment.
  • The segment focuses on advances in liver-directed cancer treatment.
  • The company is recognized for its work in interventional oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+96%
120-day peak, hindsight
Typical move
26.5%
average across 3 past catalysts
Lead asset
Hepzato Kit (melphalan HDS)
Phase 3 · Metastatic Ocular Melanoma

Full Press Release Details

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday, November 15, 2026. A podcast is also expected to be released following the television broadcast.

Frequently Asked Questions

When will Delcath Systems be featured on Health Uncensored?

The segment will air on November 15, 2026.

What is the focus of the segment featuring Delcath Systems?

It will highlight advances in liver-directed cancer treatment.

Who is hosting the segment on Delcath Systems?

The segment is hosted by Dr. Drew.

Will there be additional content after the television segment?

Yes, a podcast will be released following the broadcast.

ShareAdd on Google
Tags: DCTH Delcath Systems liver cancer interventional oncology Dr. Drew
Last updated: Nov 11, 2026

Biotech snapshot

Cash runway
$104M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Hepzato Kit (melphalan HDS)Phase 3
Metastatic Ocular Melanoma →

Catalyst track record

+96%
best trade around DCTH's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for DCTH.

See every catalyst's timing & PoA →